Treatment journey of patients with hepatocellular carcinoma using real-world data in British Columbia, Canada.

IF 1.2 Q4 ONCOLOGY

Hepatic Oncology Pub Date : 2024-03-14 eCollection Date: 2023-12-01 DOI:10.2217/hep-2023-0004

Soo Jin Seung, Hasnain Saherawala, Brandon Zagorski, Carman Tong, Howard Lim, Peter Kim, Vladimir Marquez, Sharlene Gill, David Liu, Janine M Davies

{"title":"Treatment journey of patients with hepatocellular carcinoma using real-world data in British Columbia, Canada.","authors":"Soo Jin Seung, Hasnain Saherawala, Brandon Zagorski, Carman Tong, Howard Lim, Peter Kim, Vladimir Marquez, Sharlene Gill, David Liu, Janine M Davies","doi":"10.2217/hep-2023-0004","DOIUrl":null,"url":null,"abstract":"Aim: This study examined treatment patterns, survival outcomes and healthcare costs related to hepatocellular carcinoma (HCC) in British Columbia.Methods: The study utilized data from two physician databases (HCC and MOTION) and the provincial British Columbia transplant database.Results: The analysis revealed diverse treatment approaches and identified the varying treatment journeys of patients. Liver transplant and systemic therapies demonstrated improved survival rates. However, there was a scarcity of Canadian-specific cost data.Conclusion: The research emphasizes the complexities of managing HCC and underscores the need for personalized treatment strategies to enhance patient outcomes. These findings contribute valuable insights into HCC management and provide a foundation for future studies and interventions aimed at optimizing care and resource allocation.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10941055/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/hep-2023-0004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: This study examined treatment patterns, survival outcomes and healthcare costs related to hepatocellular carcinoma (HCC) in British Columbia.

Methods: The study utilized data from two physician databases (HCC and MOTION) and the provincial British Columbia transplant database.

Results: The analysis revealed diverse treatment approaches and identified the varying treatment journeys of patients. Liver transplant and systemic therapies demonstrated improved survival rates. However, there was a scarcity of Canadian-specific cost data.

Conclusion: The research emphasizes the complexities of managing HCC and underscores the need for personalized treatment strategies to enhance patient outcomes. These findings contribute valuable insights into HCC management and provide a foundation for future studies and interventions aimed at optimizing care and resource allocation.

查看原文本刊更多论文

利用加拿大不列颠哥伦比亚省的真实数据了解肝细胞癌患者的治疗历程。

目的：本研究调查了不列颠哥伦比亚省与肝细胞癌（HCC）相关的治疗模式、生存结果和医疗费用：研究利用了两个医生数据库（HCC 和 MOTION）以及不列颠哥伦比亚省移植数据库中的数据：分析结果显示了不同的治疗方法，并确定了患者不同的治疗历程。肝移植和系统疗法提高了存活率。然而，针对加拿大的成本数据却很少：这项研究强调了管理 HCC 的复杂性，并强调需要个性化的治疗策略来提高患者的治疗效果。这些研究结果为 HCC 的管理提供了宝贵的见解，并为今后旨在优化护理和资源分配的研究和干预措施奠定了基础。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.